Phenformin was discovered in 1957 by Ungar, Freedman and [[Seymour Shapiro]], working for the US Vitamin Corporation. Clinical trials begun in 1958 showed it to be effective, but with gastrointestinal side effects.<ref name=McKendry1959>{{cite journal |author=McKendry JB, Kuwayti K, Rado PP |title=Clinical Experience with DBI (Phenformin) in the Management of Diabetes |journal=Can Med Assoc J |volume=80 |issue=10 |pages=773–8 |date=May 1959 |pmid=13652024 |pmc=1831029|last2=Kuwayti |last3=Rado }}</ref>

 
Laboratory studies attribute these apparent effects to inhibition of [[mTOR]], inhibition of [[NADH:ubiquinone reductase (H+-translocating)|complex I]], with phenformin being a more potent inhibitor than metformin,<ref name=2015revWeinberg>{{Cite journal|last=Weinberg|first=Samuel E|last2=Chandel|first2=Navdeep S|title=Targeting mitochondria metabolism for cancer therapy|url=http://www.nature.com/doifinder/10.1038/nchembio.1712|journal=Nature Chemical Biology|volume=11|issue=1|pages=9–15|doi=10.1038/nchembio.1712|pmc=4340667|pmid=25517383|year=2015}}</ref><ref name=2015revPryor>Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015 Nov 1;471(3):307-22. Review. {{PMID|26475449}} [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613459/  PMC 4613459]</ref> and activation of [[AMP-activated protein kinase]].<ref>Leone A, et al. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res. 2014;159:355-76. Review. {{PMID|24114491}}</ref>  It appears that  inhibition of complex I may cause diminished [[TCA cycle]] intermediate production and decreased mitochondrial [[Adenosine triphosphate|ATP]] production thus resulting in [[AMPK]] activation and lower [[mTOR]] activity.<ref name=2015revWeinberg/>
